{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:37:36Z","timestamp":1789904256540,"version":"4.0.1"},"reference-count":39,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:p>BACKGROUND. The incidence of and mortality from invasive pneumococcal disease are significantly higher in children with sickle cell disease than in the general pediatric population. The objective of this population-based study was to assess the effect of pneumococcal conjugate vaccine on rates of invasive pneumococcal disease among children with sickle cell disease.<\/jats:p><jats:p>PATIENTS AND METHODS. Records, including the history of pneumococcal conjugate vaccine administration, of 1247 children born after 1983 residing in metropolitan Atlanta, Georgia, with confirmed hemoglobinopathies were linked to an active surveillance database for invasive pneumococcal disease for the period of January 1, 1995, through January 1, 2003. The incidence of invasive pneumococcal disease and the percentage of rate reduction were estimated before and after pneumococcal conjugate vaccine licensure. Survival analysis was used to estimate the effect of pneumococcal conjugate vaccine on invasive pneumococcal disease rates while accounting for herd immunity.<\/jats:p><jats:p>RESULTS. A significant decline in invasive pneumococcal disease in children with sickle cell disease \u226410 years of age was noted after pneumococcal conjugate vaccine licensure, from 1.7 infections per 100 person-years (1995\u20132000) to 0.5 infections per 100 person-years (2001\u20132002), which represents a 68% reduction. The effectiveness of \u22651 dose of pneumococcal conjugate vaccine was estimated by crude analysis to be 84.5% and by stratified survival analysis to be 81.4% when controlling for the presence of herd immunity in the 2 years after pneumococcal conjugate vaccine licensure. Serotype 6A invasive pneumococcal disease represented 36% of invasive pneumococcal disease before pneumococcal conjugate vaccine licensure and 0% after pneumococcal conjugate vaccine licensure, suggesting a protective effect against this pneumococcal conjugate vaccine-related serotype.<\/jats:p><jats:p>CONCLUSIONS. Invasive pneumococcal disease significantly decreased in children with sickle cell disease \u226410 years of age after pneumococcal conjugate vaccine licensure. Pneumococcal conjugate vaccine was effective even when controlling for herd immunity. Extending guideline recommendations for catch-up vaccination beyond 4 years of age should be considered.<\/jats:p>","DOI":"10.1542\/peds.2007-0018","type":"journal-article","created":{"date-parts":[[2008,2,29]],"date-time":"2008-02-29T14:48:09Z","timestamp":1204296489000},"page":"562-569","source":"Crossref","is-referenced-by-count":143,"title":["Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease in the First Decade of Life"],"prefix":"10.1542","volume":"121","author":[{"given":"Thomas V.","family":"Adamkiewicz","sequence":"first","affiliation":[{"name":"Department of Family Medicine, Morehouse School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Silk","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Howgate","sequence":"additional","affiliation":[{"name":"School of Medicine, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Baughman","sequence":"additional","affiliation":[{"name":"School of Medicine, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Strayhorn","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Morehouse School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M.","family":"Farley","sequence":"additional","affiliation":[{"name":"School of Medicine, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,3,1]]},"reference":[{"key":"2021120905472442200_R1","doi-asserted-by":"crossref","unstructured":"Powars D, Overturf G, Weiss J, Lee S, Chan L. Pneumococcal septicemia in children with sickle cell anemia: changing trend of survival. JAMA.1981;245(18):1839\u20131842","DOI":"10.1001\/jama.245.18.1839"},{"key":"2021120905472442200_R2","doi-asserted-by":"crossref","unstructured":"Zarkowsky HS, Gallagher D, Gill FM, et al. Bacteremia in sickle hemoglobinopathies. J Pediatr.1986;109(4):579\u2013585","DOI":"10.1016\/S0022-3476(86)80216-5"},{"key":"2021120905472442200_R3","doi-asserted-by":"crossref","unstructured":"Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med.1986;314(25):1593\u20131599","DOI":"10.1056\/NEJM198606193142501"},{"key":"2021120905472442200_R4","doi-asserted-by":"crossref","unstructured":"Hord J, Byrd R, Stowe L, Windsor B, Smith-Whitley K. Streptococcus pneumoniae sepsis and meningitis during the penicillin prophylaxis era in children with sickle cell disease. J Pediatr Hematol Oncol l.2002;24(6):470\u2013472","DOI":"10.1097\/00043426-200208000-00012"},{"key":"2021120905472442200_R5","doi-asserted-by":"crossref","unstructured":"Adamkiewicz TV, Sarnaik S, Buchanan GR, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr.2003;143(4):438\u2013444","DOI":"10.1067\/S0022-3476(03)00331-7"},{"key":"2021120905472442200_R6","doi-asserted-by":"crossref","unstructured":"Berkovitch M, Papadouris D, Shaw D, Onuaha N, Dias C, Olivieri NF. Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease. Br J Clin Pharmacol.1998;45(6):605\u2013607","DOI":"10.1046\/j.1365-2125.1998.00730.x"},{"key":"2021120905472442200_R7","doi-asserted-by":"crossref","unstructured":"Elliott V, Morgan S, Day S, Mollerup LS, Wang W. Parental health beliefs and compliance with prophylactic penicillin administration in children with sickle cell disease. J Pediatr Hematol Oncol.2001;23(2):112\u2013116","DOI":"10.1097\/00043426-200102000-00009"},{"key":"2021120905472442200_R8","doi-asserted-by":"crossref","unstructured":"Teach SJ, Lillis KA, Grossi M. Compliance with penicillin prophylaxis in patients with sickle cell disease. Arch Pediatr Adolesc Med.1998;152(3):274\u2013278","DOI":"10.1001\/archpedi.152.3.274"},{"key":"2021120905472442200_R9","doi-asserted-by":"crossref","unstructured":"Sox CM, Cooper WO, Koepsell TD, DiGiuseppe DL, Christakis DA. Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease. JAMA.2003;290(8):1057\u20131061","DOI":"10.1001\/jama.290.8.1057"},{"key":"2021120905472442200_R10","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics2000;106(2):362\u2013366","DOI":"10.1542\/peds.106.2.362"},{"key":"2021120905472442200_R11","unstructured":"Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.2000;49(RR-9):1\u201335"},{"key":"2021120905472442200_R12","doi-asserted-by":"crossref","unstructured":"Bjornson AB, Falletta JM, Verter JI, et al. Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. J Pediatr.1996;129(6):828\u2013835","DOI":"10.1016\/S0022-3476(96)70026-4"},{"key":"2021120905472442200_R13","doi-asserted-by":"crossref","unstructured":"Rao SP, Rajkumar K, Schiffman G, Desai N, Unger C, Miller ST. Anti-pneumococcal antibody levels three to seven years after first booster immunization in children with sickle cell disease, and after a second booster. J Pediatr.1995;127(4):590\u2013592","DOI":"10.1016\/S0022-3476(95)70119-2"},{"key":"2021120905472442200_R14","unstructured":"Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J.2000;19(3):187\u2013195"},{"key":"2021120905472442200_R15","doi-asserted-by":"crossref","unstructured":"Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med.2003;349(14):1341\u20131348","DOI":"10.1056\/NEJMoa035060"},{"key":"2021120905472442200_R16","doi-asserted-by":"crossref","unstructured":"Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet.2005;365(9465):1139\u20131146","DOI":"10.1016\/S0140-6736(05)71876-6"},{"key":"2021120905472442200_R17","doi-asserted-by":"crossref","unstructured":"Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med.2003;348(18):1737\u20131746","DOI":"10.1056\/NEJMoa022823"},{"key":"2021120905472442200_R18","doi-asserted-by":"crossref","unstructured":"Flannery B, Schrag S, Bennett NM, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus\u2008pneumoniae infections. JAMA.2004;291(18):2197\u20132203","DOI":"10.1001\/jama.291.18.2197"},{"key":"2021120905472442200_R19","doi-asserted-by":"crossref","unstructured":"Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA.2005;294(16):2043\u20132051","DOI":"10.1001\/jama.294.16.2043"},{"key":"2021120905472442200_R20","doi-asserted-by":"crossref","unstructured":"Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med.2006;354(14):1455\u20131463","DOI":"10.1056\/NEJMoa051642"},{"key":"2021120905472442200_R21","doi-asserted-by":"crossref","unstructured":"Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis.2006;193(11):1487\u20131494","DOI":"10.1086\/503805"},{"key":"2021120905472442200_R22","doi-asserted-by":"crossref","unstructured":"Musher DM. Pneumococcal vaccine: direct and indirect (\u201cherd\u201d) effects. N Engl J Med.2006;354(14):1522\u20131524","DOI":"10.1056\/NEJMe068038"},{"key":"2021120905472442200_R23","doi-asserted-by":"crossref","unstructured":"Schuchat A, Hilger T, Zell E, et al. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis.2001;7(1):92\u201399","DOI":"10.3201\/eid0701.010114"},{"key":"2021120905472442200_R24","doi-asserted-by":"crossref","unstructured":"Papadea C, Eckman JR, Kuehnert RS, Platt AF. Comparison of liquid and dried blood for neonatal hemoglobinopathy screening: laboratory and programmatic issues. Pediatrics.1994;93(3):427\u2013432","DOI":"10.1542\/peds.93.3.427"},{"key":"2021120905472442200_R25","unstructured":"Serjeant GR, Serjeant B. Sickle Cell Disease. Oxford, United Kingdom: Oxford University Press;2001:456\u2013471"},{"key":"2021120905472442200_R26","unstructured":"National Heart, Lung, Blood Institute. The Management of Sickle Cell Disease. Bethesda, MD: National Heart, Lung, Blood Institute;2002"},{"key":"2021120905472442200_R27","unstructured":"Pickering LK, ed. Red Book: Report of the Committee on Infectious Disease. Elk Grove Village, IL: American Academy of Pediatrics; 2003:26\u201331"},{"key":"2021120905472442200_R28","unstructured":"National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. NCCLS document M100-S12. Wayne, PA: National Committee for Clinical Laboratory Standards;2002"},{"key":"2021120905472442200_R29","unstructured":"Serjeant GR, Serjeant B. Sickle Cell Disease. Oxford, United Kingdom: Oxford University Press;2001:31\u201340"},{"key":"2021120905472442200_R30","unstructured":"Hennekens CH. Epidemiology in Medicine. Boston, MA: Little, Brown and Company;1987:77\u201396"},{"key":"2021120905472442200_R31","unstructured":"Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. Hoboken, NJ: Wiley;1999:304"},{"key":"2021120905472442200_R32","doi-asserted-by":"crossref","unstructured":"Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc.1989;84(408):1074\u20131078","DOI":"10.1080\/01621459.1989.10478874"},{"key":"2021120905472442200_R33","doi-asserted-by":"crossref","unstructured":"Halasa NB, Shanka SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis.2007;44(11):1428\u20131433","DOI":"10.1086\/516781"},{"key":"2021120905472442200_R34","doi-asserted-by":"crossref","unstructured":"Mahon BE, Hsu K, Karumuri S, et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine.2006;24(14):2514\u20132520","DOI":"10.1016\/j.vaccine.2005.12.025"},{"key":"2021120905472442200_R35","doi-asserted-by":"crossref","unstructured":"Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet.2006;368(9546):1495\u20131502","DOI":"10.1016\/S0140-6736(06)69637-2"},{"key":"2021120905472442200_R36","doi-asserted-by":"crossref","unstructured":"Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus\u2008pneumoniae in Atlanta. N Engl J Med.1995;333(8):481\u2013486","DOI":"10.1056\/NEJM199508243330803"},{"key":"2021120905472442200_R37","doi-asserted-by":"crossref","unstructured":"Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus\u2008pneumoniae in the United States. N Engl J Med.2000;343(26):1917\u20131924","DOI":"10.1056\/NEJM200012283432603"},{"key":"2021120905472442200_R38","doi-asserted-by":"crossref","unstructured":"Bodenheimer T. Wagner EH. Grumbach K. Improving primary care for patients with chronic illness. JAMA.2002;288(14):1775\u20131779","DOI":"10.1001\/jama.288.14.1775"},{"key":"2021120905472442200_R39","doi-asserted-by":"crossref","unstructured":"Bodenheimer T. Wagner EH. Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA.2002;288(15):1909\u20131914","DOI":"10.1001\/jama.288.15.1909"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/3\/562\/1124122\/zpe00308000562.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/3\/562\/1124122\/zpe00308000562.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T19:06:02Z","timestamp":1684263962000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/3\/562\/72790\/Effectiveness-of-the-7-Valent-Pneumococcal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,3,1]]},"published-print":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-0018","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,1]]}}}